These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 38450197)

  • 1. Retraction: The value, diagnostic efficacy and clinical significance of functional magnetic resonance imaging in evaluating the efficacy of neoadjuvant chemotherapy in patients with triple negative breast cancer.
    Frontiers Editorial Office
    Front Oncol; 2024; 14():1383383. PubMed ID: 38450197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The value, diagnostic efficacy and clinical significance of functional magnetic resonance imaging in evaluating the efficacy of neoadjuvant chemotherapy in patients with triple negative breast cancer.
    He X; Wang Z; Zhou Y; Feng Y
    Front Oncol; 2023; 13():1132186. PubMed ID: 37064088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Magnetic resonance examination to predict pathological complete response following neoadjuvant chemotherapy: when is it appropriate for HER2-positive and triple-negative breast cancers?
    Okamoto S; Yamada T; Kanemaki Y; Kojima Y; Tsugawa K; Nakajima Y
    Breast Cancer; 2016 Sep; 23(5):789-96. PubMed ID: 26437647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Features from Computerized Texture Analysis of Breast Cancers at Pretreatment MR Imaging Are Associated with Response to Neoadjuvant Chemotherapy.
    Chamming's F; Ueno Y; Ferré R; Kao E; Jannot AS; Chong J; Omeroglu A; Mesurolle B; Reinhold C; Gallix B
    Radiology; 2018 Feb; 286(2):412-420. PubMed ID: 28980886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of the relevance between molecular subtypes and efficacy of neoadjuvant chemotherapy in breast cancer as well as its prognostic factors.
    Li F; Ma L; Geng C; Liu C; Deng H; Yue M; Ding Y; Wang X; Liu Y
    Pathol Res Pract; 2018 Aug; 214(8):1166-1172. PubMed ID: 29945816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application of triple evaluation method in predicting the efficacy of neoadjuvant therapy for breast cancer.
    Han X; Li H; Dong SS; Zhou SY; Wang CH; Guo L; Yang J; Zhang GL
    World J Surg Oncol; 2023 Mar; 21(1):116. PubMed ID: 36978164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A study on the predictive and evaluational value of molecular subtypes and dynamic contrast-enhanced magnetic resonance imaging of neoadjuvant chemotherapy for breast cancer].
    Liu WQ; Ye JM; Xu L; Liu Q; Zhao JX; Duan XN; Liu YH
    Zhonghua Wai Ke Za Zhi; 2013 Aug; 51(8):706-9. PubMed ID: 24252676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of pathological response to neoadjuvant chemotherapy in breast cancer patients by imaging.
    Kaise H; Shimizu F; Akazawa K; Hasegawa Y; Horiguchi J; Miura D; Kohno N; Ishikawa T
    J Surg Res; 2018 May; 225():175-180. PubMed ID: 29605029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer.
    Keam B; Im SA; Kim HJ; Oh DY; Kim JH; Lee SH; Chie EK; Han W; Kim DW; Moon WK; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Nov; 7():203. PubMed ID: 17976237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monitoring Serum VEGF in Neoadjuvant Chemotherapy for Patients with Triple-Negative Breast Cancer: A New Strategy for Early Prediction of Treatment Response and Patient Survival.
    Wang RX; Chen S; Huang L; Zhou Y; Shao ZM
    Oncologist; 2019 Jun; 24(6):753-761. PubMed ID: 30126858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the efficacy of neoadjuvant chemotherapy for breast cancer using diffusion-weighted imaging and dynamic contrast-enhanced magnetic resonance imaging.
    Xu HD; Zhang YQ
    Neoplasma; 2017; 64(3):430-436. PubMed ID: 28253722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene signature-based prediction of triple-negative breast cancer patient response to Neoadjuvant chemotherapy.
    Zhao Y; Schaafsma E; Cheng C
    Cancer Med; 2020 Sep; 9(17):6281-6295. PubMed ID: 32692484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diffusion-weighted imaging in assessing pathological response of tumor in breast cancer subtype to neoadjuvant chemotherapy.
    Liu S; Ren R; Chen Z; Wang Y; Fan T; Li C; Zhang P
    J Magn Reson Imaging; 2015 Sep; 42(3):779-87. PubMed ID: 25580585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing the accuracy of conventional gadolinium-enhanced breast MRI in measuring the nodal response to neoadjuvant chemotherapy (NAC) in breast cancer.
    Murphy LC; Quinn EM; Razzaq Z; Brady C; Livingstone V; Duddy L; Barry J; Redmond HP; Corrigan MA
    Breast J; 2020 Nov; 26(11):2151-2156. PubMed ID: 33176396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Accuracy of breast magnetic resonance imaging in evaluating the response to neoadjuvant chemotherapy: a study of 310 cases at a cancer center.
    Negrão EMS; Bitencourt AGV; de Souza JA; Marques EF
    Radiol Bras; 2019; 52(5):299-304. PubMed ID: 31656346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and validation of a nomogram based on pretreatment dynamic contrast-enhanced MRI for the prediction of pathologic response after neoadjuvant chemotherapy for triple-negative breast cancer.
    Li Y; Chen Y; Zhao R; Ji Y; Li J; Zhang Y; Lu H
    Eur Radiol; 2022 Mar; 32(3):1676-1687. PubMed ID: 34767068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant versus neoadjuvant chemotherapy in triple-negative breast cancer patients with BRCA mutations.
    Clifton K; Gutierrez-Barrera A; Ma J; Bassett R; Litton J; Kuerer H; Moulder S; Albarracin C; Hortobagyi G; Arun B
    Breast Cancer Res Treat; 2018 Jul; 170(1):101-109. PubMed ID: 29470805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Significance of Breast Cancer Molecular Subtypes and Ki67 Expression as a Predictive Value for Pathological Complete Response following Neoadjuvant Chemotherapy: Experience from a Tertiary Care Center in Lebanon.
    Atoui A; Bou Zerdan M; El Mahmoud A; Chamseddine N; Hamad L; Assi HI
    Int J Breast Cancer; 2022; 2022():1218128. PubMed ID: 35190777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.
    Loibl S; O'Shaughnessy J; Untch M; Sikov WM; Rugo HS; McKee MD; Huober J; Golshan M; von Minckwitz G; Maag D; Sullivan D; Wolmark N; McIntyre K; Ponce Lorenzo JJ; Metzger Filho O; Rastogi P; Symmans WF; Liu X; Geyer CE
    Lancet Oncol; 2018 Apr; 19(4):497-509. PubMed ID: 29501363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct comparison of magnetic resonance imaging and pathological shrinkage patterns of triple-negative breast cancer after neoadjuvant chemotherapy.
    Yoshikawa K; Ishida M; Kan N; Yanai H; Tsuta K; Sekimoto M; Sugie T
    World J Surg Oncol; 2020 Jul; 18(1):177. PubMed ID: 32693794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.